Sera Prognostics (SERA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 Jun, 2026Executive summary
Annual meeting scheduled for June 4, 2026, with proxy materials distributed starting April 24, 2026.
Supplement issued to update shareholders on a change in board nominees.
Voting matters and shareholder proposals
Jeffrey T. Elliott, previously nominated for re-election, has resigned effective June 4, 2026, and is no longer a nominee.
Board size reduced to seven directors; no substitute nominee will be named.
All other nominees remain up for re-election; proxy cards remain valid, but votes for Elliott will be disregarded.
No changes to other agenda items in the proxy statement.
Board of directors and corporate governance
Elliott’s resignation was not due to any disagreement regarding company operations, policies, or practices.
Board composition adjusted to reflect the reduced number of directors.
Latest events from Sera Prognostics
- PreTRM enables early, accurate preterm birth risk prediction, reducing NICU admissions and costs.SERA
Corporate presentation - Illinois Medicaid coverage, new partnerships, and clinical data drove revenue growth despite net loss.SERA
Q2 2026 - Breakthrough biomarker test and preventive bundle cut NICU admissions and costs, driving adoption.SERA
TD Cowen 45th Annual Healthcare Conference - Directors were re-elected and auditors ratified, with shareholder engagement and risk disclosures.SERA
AGM 2026 - Commercial focus accelerates after PRIME results, with reimbursement and awareness as top priorities.SERA
Jefferies Global Healthcare Conference 2026 - Strong trial results drive rapid state and payer engagement for preterm birth screening.SERA
TD Cowen 46th Annual Health Care Conference - PreTRM enables early, accurate preterm birth risk prediction, improving outcomes and reducing costs.SERA
Corporate presentation - Net loss of $8.4M on $14,000 revenue, with cash runway extended through 2029.SERA
Q1 2026 - Q1 2025 revenue grew to $38,000; cash rose to $114.2M amid Medicaid-focused PreTRM expansion.SERA
Q1 2025